Cargando…

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?

Overactive bladder (OAB) syndrome is a common, complex, and challenging condition. To assist the management of these patients, the European Association of Urology (EAU) updates its guidelines annually. This review reports the presentations from the symposium titled “Dealing with complex OAB patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Heesakkers, John, Espuña Pons, Montserrat, Toozs Hobson, Philip, Chartier-Kastler, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673033/
https://www.ncbi.nlm.nih.gov/pubmed/29184855
http://dx.doi.org/10.2147/RRU.S146746
_version_ 1783276538450411520
author Heesakkers, John
Espuña Pons, Montserrat
Toozs Hobson, Philip
Chartier-Kastler, Emmanuel
author_facet Heesakkers, John
Espuña Pons, Montserrat
Toozs Hobson, Philip
Chartier-Kastler, Emmanuel
author_sort Heesakkers, John
collection PubMed
description Overactive bladder (OAB) syndrome is a common, complex, and challenging condition. To assist the management of these patients, the European Association of Urology (EAU) updates its guidelines annually. This review reports the presentations from the symposium titled “Dealing with complex OAB patient profiles: in or out of the EAU guidelines?” held at the 32nd EAU Annual Congress in March 2017 in London. The symposium focused on three groups of OAB patients: women who may also suffer pelvic organ prolapse, stress urinary incontinence, the genitourinary syndrome of menopause (GSM); patients at risk of cognitive impairment; and elderly patients. The aim of the symposium was to determine how the 2017 EAU guidelines can best assist physicians, as well as to assess the benefits of fesoterodine in these patients. The EAU guidelines recommend antimuscarinic agents (grade A) for the medical treatment of OAB. In women, OAB is correlated with GSM, both of which are underdiagnosed and undertreated. Fesoterodine decreases OAB symptoms and the associated limitation of physical activity. A combination of fesoterodine and vaginal estrogens is appropriate for OAB associated with GSM. In patients at risk of cognitive impairment, prescribers should pay particular attention to the choice of medication. Fesoterodine is a Pgp substrate with limited ability to cross the blood–brain barrier, which may explain the lack of negative effects on the central nervous system observed in clinical trials of this agent. OAB should not be regarded as a normal consequence of aging. Fesoterodine has been extensively investigated in the elderly, and is the only anticholinergic drug licensed for OAB in this population, rated B (beneficial) according to the Fit for the Aged classification for lower-urinary-tract symptoms. The EAU guidelines are a valuable resource for physicians managing patients with OAB, and the pharmacological properties of fesoterodine offer credible clinical advantages in these three patient groups.
format Online
Article
Text
id pubmed-5673033
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56730332017-11-28 Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines? Heesakkers, John Espuña Pons, Montserrat Toozs Hobson, Philip Chartier-Kastler, Emmanuel Res Rep Urol Review Overactive bladder (OAB) syndrome is a common, complex, and challenging condition. To assist the management of these patients, the European Association of Urology (EAU) updates its guidelines annually. This review reports the presentations from the symposium titled “Dealing with complex OAB patient profiles: in or out of the EAU guidelines?” held at the 32nd EAU Annual Congress in March 2017 in London. The symposium focused on three groups of OAB patients: women who may also suffer pelvic organ prolapse, stress urinary incontinence, the genitourinary syndrome of menopause (GSM); patients at risk of cognitive impairment; and elderly patients. The aim of the symposium was to determine how the 2017 EAU guidelines can best assist physicians, as well as to assess the benefits of fesoterodine in these patients. The EAU guidelines recommend antimuscarinic agents (grade A) for the medical treatment of OAB. In women, OAB is correlated with GSM, both of which are underdiagnosed and undertreated. Fesoterodine decreases OAB symptoms and the associated limitation of physical activity. A combination of fesoterodine and vaginal estrogens is appropriate for OAB associated with GSM. In patients at risk of cognitive impairment, prescribers should pay particular attention to the choice of medication. Fesoterodine is a Pgp substrate with limited ability to cross the blood–brain barrier, which may explain the lack of negative effects on the central nervous system observed in clinical trials of this agent. OAB should not be regarded as a normal consequence of aging. Fesoterodine has been extensively investigated in the elderly, and is the only anticholinergic drug licensed for OAB in this population, rated B (beneficial) according to the Fit for the Aged classification for lower-urinary-tract symptoms. The EAU guidelines are a valuable resource for physicians managing patients with OAB, and the pharmacological properties of fesoterodine offer credible clinical advantages in these three patient groups. Dove Medical Press 2017-10-31 /pmc/articles/PMC5673033/ /pubmed/29184855 http://dx.doi.org/10.2147/RRU.S146746 Text en © 2017 Heesakkers et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Heesakkers, John
Espuña Pons, Montserrat
Toozs Hobson, Philip
Chartier-Kastler, Emmanuel
Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title_full Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title_fullStr Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title_full_unstemmed Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title_short Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
title_sort dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the eau guidelines?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673033/
https://www.ncbi.nlm.nih.gov/pubmed/29184855
http://dx.doi.org/10.2147/RRU.S146746
work_keys_str_mv AT heesakkersjohn dealingwithcomplexoveractivebladdersyndromepatientprofileswithfocusonfesoterodineinoroutoftheeauguidelines
AT espunaponsmontserrat dealingwithcomplexoveractivebladdersyndromepatientprofileswithfocusonfesoterodineinoroutoftheeauguidelines
AT toozshobsonphilip dealingwithcomplexoveractivebladdersyndromepatientprofileswithfocusonfesoterodineinoroutoftheeauguidelines
AT chartierkastleremmanuel dealingwithcomplexoveractivebladdersyndromepatientprofileswithfocusonfesoterodineinoroutoftheeauguidelines